Combined approach including taxing unhealthy foods, restricting food advertising and better labeling are among most cost-effective ways to reduce obesity in nations of all incomes

November 10, 2010

The third paper in The Lancet Series on Chronic Diseases and Development examines a range of measures to combat obesity in nations of all incomes, and concludes that a combined approach of taxing unhealthy foods (and/or reducing tax on healthy foods), restricting food advertising, and improving labeling is among the most cost-effective ways to impact on obesity in all nations. These measures would add nearly 7 million life years in good health over the next two decades in seven countries covering almost half of the world population, at an average annual cost of less than $1 per head. The paper is by a team of researchers from the Organisation for Economic Co-operation and Development, Paris, France, and from the World Health Organization.

The authors looked at strategies to tackle risk factors for obesity in seven countries: Brazil, China, India, Mexico, Russia, South Africa, and, for comparison, England. In all of these countries obesity and its related chronic diseases are a big problem. Seven in 10 Mexican adults are overweight or obese. China now has the same rates of diabetes (92 million cases) as the USA. Obesity rates have tripled in Brazilian men and doubled in Brazilian women between 1975 and 2003. The United Kingdom (including England) is the fattest country in Europe, and overweight rates will rise a further 10% over the next 10 years. In this analysis, the authors compared these strategies with the alternative strategy of no prevention plus treatment of cardiovascular disease or cancer only once it had developed.

As well as those interventions highlighted above, other interventions such as primary care physician counseling were also found to be effective. Targeting schoolchildren through school-based interventions was unlikely to be effective until 50 years post-implementation.

The authors say: "A multiple-intervention strategy would achieve substantially larger health gains than would individual interventions, often with an even more favourable cost-effectiveness profile." Such a strategy would include a health promotion campaign through the mass media, taxes and subsidies to incentivise the consumption of healthier foods, regulation of food advertising to children, and a compulsory food labelling scheme. This strategy would pay for itself in about half the countries examined, and in other countries it would become cost-effective after a maximum of 15 years (in South Africa).

If a comprehensive prevention strategy combining health education and government regulation were implemented today, 1 million years of life in good health would be added to India's health expectancy, and 4 million would be added to China's health expectancy within 20 years. In this time frame, the cost of gaining each year of life in good health would be $270 in India and $380 in China. In England, 270,000 years of life in good health would be added to the population's health expectancy, at a cost of $14,000 per year, well below the threshold currently used by UK National Institute for Health and Clinical Excellence (NICE) to recommend NHS funding. (currently at around US$45,000/£30,000 GBP per year of life in good health gained).

An affordable prevention package covering unhealthy diet and physical inactivity, tobacco and alcohol use, and treatment for high blood pressure and cholesterol, would cost from $1.5 per head per year (India) to $4.5 (Mexico). The estimated cost for England is not available but likely to be considerably higher. For the part specifically centred on unhealthy diet and physical activity, costs would range from $0.4 per head per year (India) to $1.2 (Russia), with the comparative cost in England of $3.8. The authors say: "This analysis clearly shows that the strategic approaches that deliver best value for money to address unhealthy diets, physical inactivity, and obesity-- improved awareness and information, appropriate fiscal measures, and enhanced regulatory mechanisms--closely match those for other key chronic disease risk factors (eg, tobacco and harmful alcohol use; high blood pressure and cholesterol)."
-end-
Dr Franco Sassi, Organisation for Economic Co-operation and Development, Paris, France. T) +33 1 45249239 E) franco.sassi@oecd.org

For full Series paper 3, see: http://press.thelancet.com/cdd3.pdf

NOTE: THE ABOVE LINK IS FOR JOURNALISTS ONLY. IF YOU WISH YOU CAN PROVIDE A LINK TO THE DEDICATED SERIES PAGE ON THE LANCET.COM, WHERE ALL USERS CAN DOWNLOAD PAPERS FOR FREE ONCE THEY HAVE REGISTERED (ALSO FREE). LINK AS BELOW:
http://www.thelancet.com/series/chronic-diseases-and-development

Lancet

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.